Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Product Development

Relmada data offer hope of safer option for depression

Relmada’s depression therapy may avoid the psychotomimetic effects of J&J’s esketamine, enabling at-home use

Sandi Wong, Staff Writer
October 16, 2019 12:05 AM UTC
Updated on Oct 22, 2019 at 11:48 PM UTC

Relmada more than doubled its share price Tuesday after reporting Phase II data hinting that REL-1017 could be as effective at treating depression as J&J’s Spravato without the psychotomimetic side effects that require physician monitoring.

Relmada Therapeutics Inc. (NASDAQ:RLMD) shares gained $15.01 (134%) to $26.20 Tuesday before giving back some of the gains to finish up 83% at $19.81...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Target Profiles

NMDA receptor